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I. INTRODUCTION

Recent accounts of human suffering by persons who are subjects of medical
research projects have ignited discussion and debate over the possible need to

IProtection of Human Subjects, 45 C.F.R. §§ 46.101-46.409 (1994).
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revise or update current protections given to such subjects. 2 Of particular
interest in this article are the federal regulations, promulgated by the
Department of Health and Human Services (DHHS), provided to protect
research participants, 3 especially as they apply to mentally disabled subjects in
medical research activities. 4 It is the contention of this writer that the
regulations are insufficient to adequately protect this group.
The concern of insufficient regulations, and their sloppy implementation, is
illustrated by the real-life experience of research participant Gregory Aller, the
first witness to testify in a congressional subcommittee hearing on May 23,
1994. 5 Mr. Aller, then a junior at the University of California at Los Angeles
(UCLA) and diagnosed with paranoid schizophrenia, spoke to Congress of his
negative and harmful experience as a subject in a schizophrenia research study
7
at UCLA. 6 Mr. Aller's plight had previously been disclosed in newspapers,
8
9
and in at least one magazine and one law journal.
Mr. Aller's testimony revealed that the consent forms he signed in order to
participate in the UCLA research were later deemed invalid because UCLAhad
omitted two basic elements of informed consent: foreseeable risks and
alternative treatments. 10 Obtaining legally effective informed consent from
research subjects is one form of protection offered by the DHHS regulations."1
Testimony also revealed that the informed consent process was performed

2

See generally Problems in Securing Informed Consent of Subjects in Experimental Trials
of Unapproved Drugs and Devices: Hearing Before the Subcomm. on Regulation, Business
Opportunities,and Technology of the House Comm. on Small Business, 103d Cong., 2d Sess.
(1994) [hereinafter Problems in Securing Informed Consent of Subjects].
345 C.F.R. §§ 46.101-46.409 (1994).
4This writer will focus on persons with schizophrenia serving as research subjects
although the term "mentally disabled" includes many more than just those with
schizophrenia. This was done to allow a more detailed analysis of the subject matter
considered while retaining a reasonable length for an articleof this type. Also, this writer
will not discuss the special situation of those persons deemed mentally incompetent.
5
Problems in Securing Informed Consent of Subjects, supra note 2, at 4-9 (statement of
Gregory Aller, Junior, UCLA).
6

1d.

7

See, e.g., Editorial, Medical Ethics in the Dock, N.Y. TIMES, Mar. 14, 1994, at A12;
Thomas H. Maugh HI,Researchers to Revise PatientConsent Procedure,L.A. TIMES, Mar. 11,
1994, at A29; Editorial, When the PatientIs Also an Experiment: Feds Find Faultwith UCLA
SchizophreniaStudy, L.A. TIMES, Mar. 11, 1994, at B6; and Philip J. Hilts, Agency Faults a

UCLA Studyfor Suffering of Mental Patients,N.Y. TIMES, March 10, 1994, at Al, All.
8
9

See, e.g., James Willwerth, Tinkering With Madness, TIME, Aug. 30,1993, at 40.

See, e.g., Jay Katz, Human Experimentation and Human Rights, 38 ST. LOUIS U. L.J. 7,
48 n.125 (Fall 1993).
IOProblems in Securing Informed Consent of Subjects, supra note 2, at 5 (statement of
Gregory Aller).
1145 C.F.R. §§ 46.116, 46.117 (1994).
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between the subject and investigator without any special safeguards such as
having a subject educator or advocate present. 12 The current regulations do not
require this form of protection for the mentally disabled but they should.
Monitoring of the subjects by the UCLA investigators during the course of the
13
research was also minimal.
The obvious problem is that UCLA did not follow the DHHS regulations on
informed consent 14 or monitor subjects adequately. Furthermore, an
examination of the DHHS regulations designed to protect research subjects
shows that the regulations are inadequate in providing protection to the
mentally disabled. The regulations refer to the mentally disabled as a
"vulnerable category of subjects," together with pregnant women, prisoners,
and children.15 The regulations proceed to give additional protections to
pregnant women, prisoners, and children, devoting a subpart to each, 16 while
providing only three additional safeguards for the mentally disabled, 17 of
which two of the three are vague. However, no subpart is devoted to the
protection of the mentally disabled. This article will demonstrate that a subpart
devoted to the protection of the mentally disabled, such as those with
schizophrenia, is necessary to avoid potential future harms such as those
suffered by Mr. Aller and his fellow subjects. Extra protection is particularly
warranted in the areas of obtaining informed consent and monitoring research
subjects.
This article begins with an in-depth discussion of the UCLA incident,
followed by the history of protecting human research subjects and a review of
the current law intended to protect research participants. Next, it explains the
nature of schizophrenia and discusses the topic of schizophrenia and the
informed consent process, explaining why persons with schizophrenia warrant
more protection than is currently given, especially in the areas of monitoring
and informed consent. This article also examines proposed ideas, from various
sources, for better protection of the mentally disabled as research subjects. This
article concludes with this writer's proposal as to how the DHHS regulations
could provide true protection to the mentally disabled, such as those with
schizophrenia, who serve as research subjects, by devising a separate subpart

12

problems in Securing Informed Consent of Subjects, supra note 2, at 54-55 (statement

of Donald Rockwell, M.D., Director, Neuro-Psychiatric Hospital, UCLA Medical
Center); see infra notes 192, 193, 207,210, 211 and accompanying text.
13

problems in Securing Informed Consent of Subjects, supra note 2, at 6-8 (statement of

Gregory Aller).
1445 C.F.R. §§ 46.116,46.117 (1994).
1545 C.F.R. §§ 46.107(a), 46.111(a)(3), and 46.111(b) (1994).
1645 C.F.R. § 46 (1994) Subpart B (§§ 46.201-46.211) (pregnant women), Subpart C
(§§ 46.301-46.306) (prisoners), and Subpart D (§§ 46.401-46.409) (children).

1745 C.F.R. §§ 46.107(a), 46.111(a)(3), and 46.111(b) (1994). See infra part mH.
C.1 for a
full discussion of this.
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to the regulations. A rationale for each proposed section of the subpart is
provided.
II. THE UCLA SCHIZOPHRENIA STUDY AND THE CONCERN IT CREATED

In the early 1980's, UCLA began a research study, on an outpatient basis,
involving persons with schizophrenia. 18 Gregory Aller became a part of this
study in the late 1980's.19 The study was divided into two phases. It began with
the researchers placing the subjects on a standardized dose of Prolixin, an
antipsychotic medication, 20 in hopes of achieving mental stability.21 In the
second phase of the study the stabilized subjects were taken off Prolixin so that
the researchers could study "the development of the disease [of schizophrenia]
and factors which may help predict its course in individuals. 22 As part of the
study, there was an agreement that medication would resume should a subject
show "significant symptoms" of their illness from lack of medication and if they
agreed to resume the medication.22
As a subject in this research, Mr. Aller was stabilized on Prolixin, while
24
working, and attending college. He was then asked to stop his medication,
after which time his psychotic symptoms returned in full force.25 Due to this
relapse, Mr. Aller's parents contacted the researchers numerous times, first
26
concerned, and then increasingly angry over their son's deteriorated state.
When an investigator finally consulted with Mr. Aller to see if he needed
medication, Mr. Aller, in a paranoid frame of mind, responded "no."27 Months
passed before Mr. Aller's medication was reinstated, and only after his father
personally took him in to receive it.28

18

Problems in Securing Informed Consent of Subjects, supra note 2, at 43-47 (statement

of Donald Rockwell, M.D.).
19 1d. at 4-9 (statement of Gregory Aller).
20

2

1d. at 5.

lId. at 45 (statement of Donald Rockwell, M.D.).

22
23
24

Problems in Securing Informed Consent of Subjects, supra note 2, at 44.
1d. at 45-46.
1d. at 5 (statement of Gregory Aller).

25

For instance, Mr. Aller had paranoid delusions that government agents were
chasing him; he woke up one night thinking that he was sprouting another leg; he
attempted to hitchhike to Washington, D.C. with the thought of assassinating the
President; he threatened to kill his father; and he threatened his mother with a butcher
knife. Id. at 6.
26
Problems in Securing Informed Consent of Subjects, supra note 2, at 6 (statement of
Gregory Aller).
27

1d.

28

Id.
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Other subjects, according to Mr. Aller's congressional testimony, suffered
similar or worse fates. For example, one subject whose medication was
withdrawn told the UCLA staff repeatedly that he was suicidal. He was
subsequently "expelled" by the researchers from the program and eventually
committed suicide by jumping from the roof of a UCLA building.29 Another
subject, who lived in the community, experienced a severe relapse from the
discontinuation of her medication, required hospitalization, and has remained
institutionalized since 1985. 30
In spite of these horrors, the Director of the Neuro-Psychiatric Hospital at
UCLA's Medical Center stood behind the Center's research and informed
consent process, although the Director admitted that it may be time to revisit
the topic of ethical guidelines in research. 31 Although Mr. Aller signed
informed consent forms prior to participating in this research, the Office for
Protection from Research Risks later declared the consent invalid because
UCLA had omitted foreseeable risks and alternative treatments.32 Thus, UCLA
violated federal regulations by disregarding elements of informed consent, one
of the protections offered to human research subjects.
The congressional hearing of May 23, 1994 brought up the issue that no
special regulations exist to guide research involving the mentally ill,33 and that
such subjects are inadequately protected. Mr. Aller remarked, "I believe that
the researchers view people with schizophrenia as subhuman" and "[t]he
system does not protect human subjects; it protects the researchers." 34
Mr. Aller's testimony reveals that special regulations to protect this group of
research participants are necessary. What would have happened to Mr. Aller if
his parents were not such strong advocates, or if they were not present at all?
If Mr. Aller had received extra assistance during the consent process, would he
have agreed to participate in the research or at least been more aware of the
consequences of participating? If the investigator's monitoring of subjects was
improved, would Mr. Aller's paranoia, a symptom of his schizophrenia that
impaired his ability to inform the researchers that he needed help, have been
detected earlier? Of course, we will never know the answers to these questions,
but the system of protection can be improved in hopes of ensuring that future
research participants like Mr. Aller are better protected.

29

1d. at 6-7.

30

Problems in Securing Informed Consent of Subjects, supra note 2, at 7-8.

31

Id. at 43-47 (statement of Donald Rockwell, M.D.).
1d. at 5 (statement of Gregory Aller).

32

33
1d. at 32 (statement of Arthur Caplan, Ph.D., Center for Bioethics, University of
Pennsylvania, Philadelphia).
34

Problems in Securing Informed Consent of Subjects, supra note 2, at 8-9 (statement of

Gregory Aller).
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IHI. THE PROTECTION OF HUMAN RESEARCH SUBJECTS

A. The History of ProtectingResearch Subjects
Modem history shows the need to protect research participants from harm.
This need was especially apparent following World War II when horrendous
and deadly "experiments" on concentration camp prisoners by Nazi
physician-experimenters were revealed. 3 5 Various forms of atrocious
experiments were performed, leading to the death or great physical harm of
each subject. 36 United States judges sat in judgment of these
physician-experimenters and, after seeing evidence of such "horrendous
non-therapeutic, nonconsensual prison research,"37 created the Nuremberg
Code. The Nuremberg Code has been declared "the most authoritative legal
and ethical document governing international research standards, and one of
the premier human rights documents in world history."38 The Nuremberg Code
contains ten provisions, the first of which speaks directly of consent. This
provision reads:
1. The voluntary consent of the human subject is absolutely essential.
This means that the person involved should have legal capacity to give
consent; should be so situated as to be able to exercise free power of
choice, without the intervention of any element of force, fraud, deceit,
duress, over-reaching, or other ulterior form of constraint or coercion;
and should have sufficient knowledge and comprehension of the elements of
the subject matter involved as to enable him to make an understandingand
enlightened decision. This latter element requires that before the
acceptance of an affirmative decision by the experimental subject there
should be made known to him the nature, duration, and purpose of
the experiment; the method and means by which it is to be conducted;
all inconveniences and hazards reasonably to be expected; and the
effects upon his health or person which may possibly come from his
participation in the experiment.
The duty and responsibility for ascertaining the quality of the
consent rests upon each individual who initiates, directs or engages in

35

George J. Annas, The Changing Landscape of Human Experimentation: Nuremberg,
Helsinki, and Beyond, 2 HEALTH MATRIx 119,120-21 (Summer 1992).
36
0ne such experiment included the "Experiments with Poison" in which prisoners
were secretly given poison in their food so that the researchers could "investigate the
effect ofvarious poisons upon human beings." If the victims did not die from the poison,
they were then killed so that the experimenters could perform autopsies on them. This
is just one example of many different experiments that were performed. THE NAZI
DocroRs AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 100

(George J.Annas & Michael A. Grodin eds., 1992).
37
Annas, supra note 35, at 121.
38
1d.
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the experiment. It is a personal duty and responsibility which may not
be delegated to another with impunity.39
Other provisions of the Nuremberg Code relate particularly to the health and
welfare of the subjects. For instance, random or unnecessary experiments may
not be performed, 40 all unnecessary suffering and injury, physical or mental,
must be avoided, 4 1 and the highest degree of skill and care should be provided
during the experiment by scientifically qualified persons. 42
The United States also saw its own horror stories of unethical research. For
instance, in the 1970's it was discovered that 400 Black males involved in the
Tuskegee Syphilis Study, sponsored by the Public Health Service, were
intentionally left untreated with the disease for years so that researchers could
study the natural progression of syphilis. 43
The next big step in the area of protecting human research subjects occurred
when the World Medical Association issued the Declaration of Helsinki in 1964,
with amendments in 1975, 1983, and 1989." The Declaration contains twelve
basic principles with recommendations from physicians to physicians
regarding research. 45 This document is ethical in nature, and is considered
more permissive or lenient than the Nuremberg Code.46
In the United States, regulations protecting human research subjects,
promulgated by the Department of Health, Education, and Welfare (now the
Department of Health and Human Services), became effective on May 30,
1974.47 In 1981 the regulations were significantly revised and codified at Title
45 Part 46 of the Code of Federal Regulations.48 The regulations have been
revised twice since 1981: in 1983 and 1991.49 Additional protections for some,

392 NUERNBERG MILITARY TRIBUNALS, TRIALS OF WAR CRIMINALS BEFORE THE
NUERNBERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAw No. 10 181-82
(1946-1949) (emphasis added).
40

Id. at 182.

41Id.
42
43

Id.
RUTH R. FADEN & TOM L. BEAUCHAMP, A HISTORY AND THEORY OF INFORMED

CONSENT 165-67 (1986).
44WORLD MEDICAL Ass'N, DECLARATION OF HELSINKI (1989), reprinted in Annas &

Grodin, supra note 36, at 331-42.
45

1d. at 340-42.

46

Annas, supra note 35, at 122.

47

ROBN L. PENSLAR, U.S. DEP'T OF HEALTH AND HUMAN SERVS., PROTECTING HUMAN
RESEARCH SUBJECTS: INSTITUTIONAL REVIEW BOARD GUIDEBOOK xviii (2d ed. 1993).
48

1d.

49

d. at xviii-xix.
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but not all, of the so-called vulnerable populations were adopted as follows:
in 1975 for pregnant women, in 1978 for prisoners, and in 1983 for children.50
Several reports and recommendations issued by the National Commission
for the Protection of Human Subjects of Biomedical and Behavioral Research
have played a vital part in identifying and recommending basic ethical
principles in research with human subjects. The Commission issued the
influential Belmont Report in 1978.51 The Belmont Report delineated three basic
ethical principles relevant to research involving human subjects: 1) respectfor
persons, which means that individuals should be treated as autonomous agents
and that personswith diminishedautonomy are entitled to protection;2) beneficence,
which is an obligation to do no harm by maximizing possible benefits and
minimizing possible harms; and 3) justice, which means that the burdens and
52
benefits of research are distributed fairly
The Belmont Report also spoke of informed consent.53The three elements of
informed consent are information, comprehension, and voluntariness.
Information includes various items a reasonable volunteer would want to
know before participating as a research subject. 54 Comprehension involves "the
subject's ability to understand [which] is a function of intelligence, rationality,
maturity and language, [and] it is necessary to adapt the presentation of the
information to the subject's capacities. Investigators are responsible for
ascertaining that the subject has comprehended the information." 55 Finally, a
true voluntary subject requires participation, void of any coercion or undue
influence.56
The Commission also issued reports and recommendations on research
involving children,5 7 prisoners, 58 fetuses, 59 and those institutionalized as

50

d. at xix.

51

NA-TONAL COMM'N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, U.S. DEP'T OF HEALTH, EDUC., AND WELFARE, PUB. No. (OS)
78-0012, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE
PROTECTIONOF HUMAN SUBJECTSOF RESEARCH (1978) [hereinafter THE BELMONT REPORT].
52

1d. at 4-10 (emphasis added).
d. at 10-14.

53

54Mid. at 11-12.
55

56

THE BELMONT REPORT, supranote 51, at 12 (emphasis added).

d. at 14.

57

NAUONAL COMM-N FOR THE PROTECTION OF HUmAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, U.S. DEPT OF HEALTH, EDUC. AND WELFARE, PUB. No. (OS)
77-0004, REPORT AND RECOMMENDATIONS. RESEARCH INVOLVING CHILDREN (1977).
58

NATIONAL COMM-N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, US. DEP'T OF HEALTH, EDUC., AND WELFARE, PUB. No. (OS)
76-131, REPORT AND RECOMMENDATIONS: RESEARCH INVOLVING PRISONERS (1976).
59
NATIONAL COMM-N FOR THE PROTECTION OF HuMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, U.S. DEP'T OF HEALTH, EDUC., AND WELFARE, PUB. No. (OS)
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"mentally infirm" which included mentally ill, mentally retarded, emotionally
disturbed, and senile individuals. 60 It is interesting to note that each of these
subgroups, with the exception of the "mentally infirm," would subsequently
61
receive additional regulatory protections when involved in research. It is
suggested that the recommended protections for the "mentally infirm" did not
evolve into regulations because they were excessively elaborate, and "to avoid
stigmatization of the mentally infirm."62 Unfortunately, vulnerable subjects,
not commissions, were left with minimal protections.
B. A General Overview of the Current Law
Federal regulations required by the Department of Health and Human
Services, appearing at 45 C.F.R. §§ 46.101-46.409 (1994), provide for the
protection of human subjects in "all research... conducted, supported or
otherwise subject to regulation by any federal department or agency."63
Research is defined as "a systematic investigation, including research
development, testing and evaluation, designed to develop or contribute to
generalized knowledge."64 A similar set of protections also exists at 21 C.F.R.
§§ 50.1-50.48 (1994), and is applicable to all "clinical investigations regulated
by the Food and Drug Administration." 65 Since the regulations are so similar,
and in order to avoid confusion, this article will focus exclusively on the
regulations issued by the Department of Health and Human Services (DHHS).
The DHHS regulations provide a number of protections for research subjects
including requiring the investigators to obtain informed consent from a
research subject prior to participating in research. 66 The regulations enumerate
eight basic elements of informed consent. 67 The eight elements are:
(1) A statement that the study involves research, an explanation of the
purposes of the research and the expected duration of the subject's

76-127, REPORT AND RECOMMENDATIONS: RESEARCH ON THE FETuS (1975).
60
NATIONAL COMM'N FOR THE PROTECTION OF HuMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, U.S. DEP'T OF HEALTH, EDUC., AND WELFARE, PUB. No. (OS)
78-0006,
REPORT
AND RECOMMENDATIONS:
RESEARCH INVOLVING
THOSE
INSTITUTIONALIZED AS MENTALLY INFIRM xvii (1978).

61See infra parts Im.C.2-4.
62

ROBERTJ. LEVINE, ETHICS AND REGULATION OF CLINICAL RESEARCH 180 (1981) (citing

Natalie Reatig, Government Regulations Affecting Psychopharmacology Research in the
United States: Implicationsfor the Future, in HUMAN PSYCHOPHARMACOLOGY: RESEARCH
AND CLINICAL PRACTICE (Graham D. Burrows & John S. Werry eds., 1981)).

6345 C.F.R. § 46.101(a) (1994).
6445 C.F.R. § 46.102(d) (1994).
6521 C.F.R. § 50.1(a) (1994).

6645 C.F.R. § 46.116 (1994).
6745 C.F.R. § 46.116(a)(1)-(a)(8) (1994).
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participation, a description of the procedures to be followed,
and
68
identification of any procedures which are experimental;
(2) A description of any reasonably foreseeable risks or discomforts to
the subject; 9
(3) A description of any benefits to the subject or to others which may
reasonably be expected from the research;
(4) A disclosure of appropriate alternative procedures or courses
of
71
treatment, if any, that might be advantageous to the subject;
(5) A statement describing the extent, if any, to which2 confidentiality
of records identifying the subject will be maintained;7
(6) For research involving more than minimal risk, an explanation as
to whether any compensation and an explanation as to whether any
medical treatments are available if injury occurs and, if sowhat they
consist of, or where further information may be obtained;
(7) An explanation of whom to contact for answers to pertinent
questions about the research and research subjects' rights, and whom
to contact in the event of a research-related injury to the subject; 74 and
(8) A statement that participation is voluntary, refusal to participate
will involve no penalty or loss of benefits to which the subject is
otherwise entitled, and the subject may discontinue participation at
any time without penalty
or loss of benefits to which the subject is
5
otherwise entitled.P
Based on the DHHS regulations, informed consent is to be documented in
one of two ways. 76 First, documentation can consist of a "written consent
document that embodies the elements of informed consent required by
§ 46.116" which the subject is to sign following an "adequate opportunity" to
read it.7 The second form allows the elements of § 46.116 to be presented orally
to the subject. However, a witness must be present and both subject and witness

6845 C.F.R. § 46.116(a)(1) (1994).
6945 C.F.R. § 46.116(a)(2) (1994), an element violated in the Gregory Aller case.
7045 C.F.R. § 46.116(a)(3) (1994).
7145 C.F.R. § 46.116(a)(4) (1994), another element violated in the Gregory Aller case.
7245 C.F.R. § 46.116(a)(5) (1994).
7345 C.F.R. § 46.116(a)(6) (1994).
7445 C.F.R. § 46.116(a)(7) (1994).
7545 C.F.R. § 46.116(a)(8) (1994).
7645 C.F.R. § 46.117 (1994).
7745 C.F.R. § 46.117(b)(1) (1994).
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must sign to verify that an oral presentation has taken place.78 The requirement
of a signed consent form can be waived if signing would result in a breach of
confidentiality and the subject, not the researcher, opts to have no
documentation, 79 or, if the "research presents no more than minimal risk of
harm to subjects and involves no procedures for which written consent is
normally required outside of the research context." 80
The DHHS regulations also protect research subjects by requiring
institutions 81 involved in research to initially review and approve research
projects through their Institutional Review Boards (IRBs). 82 The IRBs are also
required to review approved research projects at least once a year,83 and are to
ensure investigators' compliance with § 46.116. 84
Each institution is given the authority to designate its own IRB,85 but must
follow certain regulations in doing so.86 For instance, each IRB must have at
least five members with varying backgrounds, 87 at least one member's primary
concern must be in a scientific area and at least one member's primary concern
must be in a nonscientific area.88 Furthermore, each IRB must have at least one
member who has no affiliation with the institution. 89
C. ProvidingAdditional Protections to Those Deemed "Vulnerable"
The DHHS regulations also provide additional provisions for the protection
of research participants belonging to "vulnerable populations." "Vulnerable
populations" include "children, prisoners, pregnant women, mentally disabled
persons, or economically or educationally disadvantaged persons."90 An
examination of the regulations shows that pregnant women, prisoners, and
children are given additional protections, clearly delineated in a subpart

7845 C.F.R. § 46.117(b)(2) (1994).
7945 C.F.R. § 46.117(c)(1) (1994).
8045 C.F.R. § 46.117(c)(2) (1994).
81

"Institution" is defined as "any public or private entityoragency (including federal,

state, and other agencies)." 45 C.F.R. § 46.102(b) (1994).
8245 C.F.R. § 46.108 (1994).
8345 C.F.R. § 46.109(e) (1994).
8445 C.F.R. § 46.109(b) (1994).
8545 C.F.R. § 46.103(b)(2) (1994).
8645 C.F.R. § 46.107 (1994).
8745 C.F.R. § 46.107(a) (1994).
8845 C.F.R. § 46.107(c) (1994).
8945 C.F.R. § 46.107(d) (1994).
9045 C.F.R. § 46.111(a)(3) (1994).
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devoted to each of these groups.9 1 However, there are no subparts devoted to
the mentally disabled or economically or educationally disadvantaged.
1. Additional Protections for the "Mentally Disabled" Involved
as Subjects in Research
The DHHS regulations refer to the mentally disabled in two sections. First,
under "IRB membership" the DHHS regulations dictate that "[ilf an IRB
regularly reviews research that involves a vulnerable category of subjects, such
as... mentally disabled persons, consideration shall be given to the inclusion
of one or more individuals who are knowledgeable about and experienced in
working with these subjects."9 2 Second, under "Criteria for IRB approval of
research," the regulations state that IRBs are required to make certain that the
selection of research subjects is equitable. 93 The IRB is to consider the purpose
and setting of the research, and "should be particularly cognizant of the special
problems of research involving vulnerable populations, such as children,
prisoners, pregnant women, mentally disabled persons, or economically or
educationally disadvantaged persons."94 In the same section, the regulations
mandate the inclusion of "additional safeguards" in research studies "[w]hen
some or all of the subjects are likely to be vulnerable to coercion or undue
influence, such as ... mentally disabled persons," in order to "protect the rights
and welfare of these subjects."95 However, such "additional safeguards" are not
defined. It is interesting to note that these two sections apply to all "vulnerable"
subjects, so again the regulations do not devote a section exclusively to the
mentally disabled, despite declaring them a "vulnerable" group like pregnant
women, prisoners, and children.
The DHHS regulations do not provide any requirements or guidance as to
informed consent involving those individuals with severe psychiatric
disabilities such as schizophrenia. The regulations give the IRBs the
discretionary authority to require researchers to give additional information,
beyond the eight elements of informed consent outlined in § 46.116, "when in
the IRB's judgment the information would meaningfully add to the protection
of the rights and welfare of subjects."96 This is not specifically addressed to any
particular group of subjects, including the mentally disabled. The regulations
also require IRBs to observe the consent process and research as part of their

9145 C.F.R. § 46 (1994), Subpart B(§§ 46.201-46.211) (provides additional protections
for pregnant women), Subpart C (§§ 46.301-46.306) (provides additional protections for

prisoners), Subpart D (§§ 46.401-46.409) (provides additional protections for children).
There are no subparts E, F, or G.
9245 C.F.R. § 46.107(a) (1994).
9345 C.F.R. § 46.111(a)(3) (1994).
9445 C.F.R. § 46.111(a)(3) (1994).
9545 C.F.R. § 46.111(b) (1994).
9645 C.F.R. § 46.109(b) (1994).
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duty to review research at their facility. 97 Again, this general rule is not
specifically addressed to any particular group of subjects.
The InstitutionalReview Board Guidebook (the Guidebook), which is written to
provide guidance to IRBs, states, "[tIhe predominant ethical concern in research
involving individuals with psychiatric, cognitive, or developmental disorders
.is that their disorders may compromise their capacity to understand the
information presented and their ability to make a reasoned decision about
participation."98 The Guidebook mentions that the DHHS regulations require
IRBs to have "one or more individuals who are knowledgeable about and
experienced in working with those subjects" and require that "additional
safeguards are in place."99 Again, "additional safeguards" are not defined. The
Guidebook then notes, "[u]nlike research involving children, prisoners and
fetuses .... no additional DHHS regulations specifically govern research
involving persons who are cognitively impaired." 00
2. Additional Protections for Pregnant Women Involved
as Subjects in Research
The DHHS regulations, at Subpart B, provide additional protections in
connection with research involving pregnant women, fetuses, and human in
vitro fertilization. 10 1 The special protections given to pregnant women will be
looked at in this section.
According to the Guidebook, this subgroup warrants "special attention from
IRBs because of women's additional health concerns during pregnancy and
because of the need to avoid unnecessary risk to the fetus."10 2The Guidebook
adds, "[sipecial attention is justified because of the involvement of a third party
(the fetus) who may be affected but cannot give consent and because of the
need to prevent harm or injury to future members of society."103
The first protection mandates that the Secretary of DHHS establish "Ethical
Advisory Boards" to serve as advisors on any ethical issues that may be raised
by individual research proposals or by any general policies or guidelines. 104

9745 C.F.R. § 46.109(e) (1994).
98PENsLAR,supra note 47, at 6-26.
99

1d. at 6-27.
1 1d. "Cognitively impaired" is defined as having a psychiatric disorder, an organic
impairment, or a developmental disorder that affects cognitive or emotional functions
00

to the extent that capacity for judgment and reasoning is significantly diminished. Id. at

6-26.
10145 C.F.R. §§ 46.201-46.211 (1994).
102
PENSLAR, supra note 47, at 6-11.
103

Id.
10445 C.F.R. § 46.204(a) and (b) (1994).
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The Boards must be "competent to deal with medical, legal, social, ethical, and
related issues."105
The second protection requires IRBs to monitor the informed consent process
by actual participation of the IRB or through the use of "subject advocates." 106
This entails a third party overseeing the informed consent process, in at least a
sampling of the subjects, to ensure that "approved procedures for induction of
individuals into the activity are being followed." 107 This section also allows for
visits to research sites, by IRBs or subject advocates, to continually monitor and
evaluate activities "to determine if any unanticipated risks have arisen."108
The regulations forbid pregnant women from being involved as subjects in
research unless the research activity meets the health needs of the mother and
places the fetus at minimal risk. 109
3. Additional Protections for Prisoners Involved as Subjects in Research
The DHHS regulations, at Subpart C, provide additional protections in
connection with research involving prisoners. 110 These special safeguards exist
with the recognition that "prisoners may be under constraints because of their
incarceration which could affect their ability to make a truly voluntary and
uncoerced decision whether or not to participate as subjects in research." 111
The first protection requires that a majority of the IRB, exclusive of prisoner
Board members, have no affiliation with the particular prison seeking review
and approval of research at its facility.112 This section also requires that at least
one member of the IRB is a prisoner or "a prisoner representative with
1 3
appropriate background and experience to serve in that capacity."
The second protection involves additional duties placed on the IRB when
reviewing research. 114 For example, the IRB may not approve research which
would create advantages to the prisoner (in terms of medical care, quality of
food, etc.), thereby impairing his or her ability to weigh the risks of the research
against such desirable advantages in his or her limited environment.11 5 The
IRB has the duty to ensure that "information is presented in language which is
10545 C.F.R. § 46.204(a) (1994).
10645 C.F.R. § 46.205(a)(2) (1994).
10745 C.F.R. § 46.205(a)(2)(i) (1994).
10845 C.F.R. § 46.205(a)(2)(ii) (1994).
10945 C.F.R. § 46.207(a) (1994).
11045 C.F.R. §§ 46.301-46.306 (1994).
11145 C.F.R. § 46.302 (1994).
11245 C.F.R. § 46.304(a) (1994).
11345 C.F.R. § 46.304(b) (1994).
11445 C.F.R. § 46.305 (1994).
11545 C.F.R. § 46.305(a)(2) (1994).
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understandable to the subject population." 1 6 The IRB is also to determine if
follow-up examination or care of research participants, following their formal
117
participation, is needed and, if so, that adequate provisions have been made.
4. Additional Protections for Children Involved as Subjects in Research
The DHHS regulations, at Subpart D, provide additional protections in
connection with research involving children.1 1 8 According to the Guidebook,
this subgroup warrants extra protection because of children's "special
vulnerability."119 The Guidebook adds, "[tjo safeguard their interests and to
protect them from harm, special ethical and regulatory considerations are in
place for reviewing research involving children." 120
Protections for children vary depending on the amount of risks and benefits
involved. 121 Informed consent is only mentioned in this section to define
children as persons who have not reached the legal age to consent to research
participation. 122
One form of protection for children involves the IRB's requirement to solicit
the "assent" of the child to participate in research if the child is capable of
providing it.123 "Assent" is defined as an "affirmative agreement to participate
in research. Mere failure to object should not, absent affirmative agreement, be
construed as assent. 124 In determining if a child is capable of assenting, the
IRB is to consider the age, maturity, and psychological state of the child.125
Parental permission is also required. 126 "Permission" is defined as "the
agreement of parent(s) or guardian to the participation of their child or ward
127
in research."
This section also provides special protection to children considered wards
of the state or any other agency or institution. 128 The protection applies to

11645 C.F.R. § 46.305(a)(5) (1994).
11745 C.F.R. § 46.305(a)(7) (1994).
11845 C.F.R. §§ 46.401-46.409 (1994).
119

PNSLAR, supra note 47, at 6-18.

120

d.
12145 C.F.R. §§ 46.404-46.407 (1994).
12245 C.F.R. § 46.402(a) (1994).
12345 C.F.R.§§ 46.404,46.405(c), 46.406(d), 46.407(b)(2)(iii), 46.408(a) and (e) (1994).
12445 C.F.R. § 46.402(b) (1994).
12545 C.F.R. § 46.408(a) (1994).
12645 C.F.R. §§ 46.404,46.405(c), 46.406(d), 46.407(b)(2)(iii), 46.408(b) and (d) (1994).
12745 C.F.R. § 46.402(c) (1994).
12845 C.F.R. § 46.409 (1994).
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research involving greater than minimal risk 129 to the subject with no direct
benefit to the subject, or, to research involving the understanding, prevention,
or alleviation of a serious problem affecting the health and welfare of
children. 130 If such research is carried out with children who are wards, the IRB
must do the following:
[Tihe IRB shall require appointment of an advocate for each child who
is a ward, in addition to any other individual acting on behalf of the
child as guardian or in loco parentis. One individual may serve as
advocate for more than one child. The advocate shall be an individual
who has the background and experience to act in, and agrees to act in,
the best interests of the child for the duration of the child's
participation in the research and who is not associated in any way
(except in the role as advocate or member of the IRB)with the research,
the investigator(s), or the guardian organization.
In sum, the DHHS regulations recognize the mentally disabled as a
"vulnerable" group of research participants, yet fail to provide this group with
additional protections as it does so clearly and elaborately for pregnant women,
prisoners, and children. This is problematic as the mentally disabled also have
unique circumstances, which warrant special protections which are not given.
IV. THE NATURE OF SCHIZOPHRENIA

In order to think about providing more protection to persons participating
in schizophrenia research, the reader must first have an understanding of what
schizophrenia is. This is a necessary step as a significant number of people are
uninformed or misinformed about this disease. 13 2 This writer will attempt to
familiarize the reader with the disease of schizophrenia, using the testimony
of Gregory Aller,133 when possible, to illustrate key concepts.

12 9

"Minimal risk" is defined by the regulations as "the probability and magnitude of

harm or discomfort anticipated in the research are not greater in and of themselves than
those ordinarily encountered in daily life or during the performance of routine physical
or psychological examinations or tests." 45 C.F.R. § 46.102(i) (1994).
13045 C.F.R. § 46.409(a) (1994).
13145 C.F.R. § 46.409(b) (1994).
13 2

a clinical and research psychiatrist, contends that:
Despite its being a common disease, schizophrenia is remote to most
people. A remarkable number of people do not even know what
schizophrenia is. A recent survey of college freshman found that 64
percent of them believed 'multiple personalities' to be a common
symptom of schizophrenia. Schizophrenia has nothing to do with
multiple or split personalities ....
E. FULLER TORREY, SURVIVING SCHIZOPHRENIA A FAMILY MANUAL 4 (rev. ed. 1988).
Dr. E.Fuller Torrey,

13 3 Problems in Securing Informed Consent of Subjects, supra note 2, at 4-9 (statement of

Gregory Aller).
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First, some general information and statistics on schizophrenia are given.
Second, the criteria necessary to diagnose schizophrenia are reviewed and,
lastly, the course of the disease is examined.
A. General Information and Statisticson Schizophrenia
Schizophrenia has been described as "arguably the worst disease affecting
mankind 134 because of its complexity of symptoms, its potentially
135
deteriorating course, and because there is no cure for this disease.
Schizophrenia is actually a common disease in our society today. In the United
States, it is estimated that 1.2 million persons have schizophrenia, which means
'approximately one out every hundred persons in the United States will be
diagnosed with schizophrenia during his or her lifetime."136 Of this 1.2 million,
it is estimated that 482,000 live with family members in the community; 250,000
live in foster homes or board-and-care homes; 165,000 reside in nursing homes;
100,000 live alone; 85,000 are in hospitals; 87,000 are in public shelters or live
137
on the streets; and 31,000 are in jails or prisons.
Today, many persons with schizophrenia, and those with other mental
disabilities, live in the community as opposed to hospitals due to the reform
movement of deinstitutionalization. 138 This movement, started in the 1960's,
grew from society's recognition that large mental institutions had become
inhumane, warehouse-like facilities for those with chronic mental illnesses
such as schizophrenia. 139 Thus, mental hospitals began to discharge patients
to more humane facilities or, more often, to their families and the community.14o
This "emptying" of mental hospitals has significantly reduced hospital
populations: from 524,878 in 1970 to 267,638 in 1986.141
Deinstitutionalization has not been without its problems. For example, many
residents of such institutions had no families or homes to go to; facilities in the
community (e.g., the board-and-care homes) have been deemed substandard;
and a significant portion of those discharged have become homeless and vul-

134

Editorial, Where Next with PsychiatricIllness?, NATURE, Nov. 10, 1988, at 95.

135

OFFICE OF TECHNOLOGY ASSESSMENT, 102D CONG., THE BIOLOGY OF MENTAL
DISORDERS, Doc. No. OTA-BA-538, 6-7 (Sept. 1992) [hereinafter OFFICE OF TECHNOLOGY
AssESSMENT].
136 ToRREY, supra note 132, at 3.
137

1d. at 8.

13 8

ROBERT C. CARSON & JAMES N. BtrrCHER, ABNORMAL PSYCHOLOGY AND MODERN

LIFE 693 (9th ed. 1992).
13 9

140
141

1d.

1d.

1d. These figures indicate reduction of hospital patients overall, not only those with
schizophrenia. That is, the figures include other diagnoses, too.
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nerable to victimization.1 42 Of those with families, it has been observed, "there
are enormous tensions in caring for a mentally ill member,"143 with some
families experiencing "bum-out."144
The socioeconomic data on persons with schizophrenia reveal that
"[i]ndividuals who have never been married or who are divorced or separated
suffer schizophrenia two to three times as often as their married or widowed
counterparts."145 Also, compared to the general population, persons with
schizophrenia are less likely to have earned a college degree or to be employed
and, if employed, they are likely to earn less than their counterparts without
schizophrenia. 146 Schizophrenia is five times more prevalent in lower
socioeconomic groups as compared to higher socioeconomic groups. 147
B. The DiagnosticCriteriafor Schizophrenia'48
Schizophrenia is a disease characterized by a mixture of certain signs and
symptoms, involving "a range of cognitive and emotional dysfunctions," which
must persist for a specified amount of time before this disease can be
diagnosed. 149 To be diagnosed with schizophrenia, six criteria (A through F)
must be met.150
Criterion Arequires the presence of certain characteristic symptoms, referred
to as active-phase symptoms, 151 which include: (1) delusions, 152 (2)

142

CARSON &BUTCHER,supra note 138, at 694-95.

43

1 Harriet P. Lefley, An AdaptationFramework Its Meaningfor Research and Practice,in
FAMIuEs OF THE MENTALLY ILL 320 (Agnes B.Hatfield & Harriet P. Lefley eds., 1987).
144
LeRoy Spaniol &Hal Jung, Effective Coping: A ConceptualModel, in FAMILIES OF THE
MENTALLY ILL, supra note 143, at 93. Mr. Aller was fortunate to have his family advocate
for him during his ordeal at UCLA. However, not all families would/could have been

so responsive. Therefore, the protection of such subjects cannot be expected to come

from families.
145
0FCE OF TECHNOLOGY AssEsSMENT, supra note 135, at 51.
146
147

Id.
Id.

148
The information in this discussion has been obtained from the AMERICAN
PsYcHiATRIc Ass'N, DIAGNosTIc AND STATISTICAL MANUAL OF MENTAL DisoRDERs (4th
ed. 1994) [hereinafter APA], a manual used by many mental health professionals to
diagnose mental disorders. The manual is very informative and descriptive. It was
originally published by the American Psychiatric Association in 1952 and was recently
updated in 1994.
149
1d. at 274.

15 01d. at 285-86.
151

152

1d. at 273.

APA, supra note 148, at 285; e.g., 'I started to have paranoid delusions about
Government agents chasing me." Problemsin Securing Informed Consentof Subjects, supra
note 2, at 6 (statement of Gregory Aller).
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hallucinations, 153 (3) disorganized speech,154 (4) grossly disorganized
behavior 155 or catatonic behavior,156 and (5) negative symptoms 157 which
include affective flattening,158 alogia,159 or avolition. 160 If at least two of these
symptoms persist for a significant portion of time during a one-month period
(or less if successfully treated), then a diagnosis of schizophrenia is given if
161
other criteria are also met.
Criterion B requires that the person's "work, interpersonal relations, or
self-care are markedly below the level achieved prior to the onset" of the
disease. 162 Criterion C requires that continuous signs of the disease persist for
at least six months, with at least one month of symptoms which satisfy
Criterion A, 163 as stated above. Criterion D involves ruling out the diagnosis
of schizophrenia if the diagnosis of schizoaffective disorder or mood disorder
would be more appropriate.164 Criterion E also rules out schizophrenia if the
disturbance is due to the direct effects of drug abuse, medication, or a general
medical condition.165 Finally, Criterion F, reads: "If there is a history of Autistic
Disorder or another Pervasive Developmental Disorder, the additional
diagnosis of Schizophrenia is made only if prominent delusions or
hallucinations are also present for at least a month (or less if successfully
treated)." 166

153 APA, supra note 148, at 285; e.g., 'I woke up screaming actually believing that Iwas
sprouting another leg." Problemsin Securing Informed Consent of Subjects, supra note 2, at
6 (statement of Gregory Aller).
154

APA, supra note 148, at 285; e.g., the person may slip easily from one topic to

another, unable to stay on topic, or the person's "answers to questions may be obliquely
related or completely unrelated." Id. at 276.
155 Id. at 285; e.g., appearing markedly disheveled, dressing in an unusual manner. Id.
at 276.
156

APA, supra note 148, at285;e.g., "marked decrease in reactivity to the environment."

Id. at 276.
157

Id. at 285.

158Id.
159
APA, supra note 148, at 285; e.g., the person answers questions with brief and empty
replies. Id. at 276-77.
160

d. at 285; defined as "an inability to initiate and persist in goal-directed activities."

Id. at 277.
161

APA, supra note 148, at 285.

162

Id.

63

1 Id.
164
16

Id. at 285-86.
5APA, supra note 148, at 286.

166Id.
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Clinicians are warned to take cultural differences into account when
in
diagnosing schizophrenia since "[ildeas that may appear to be delusional" 167
one culture (e.g., sorcery and witchcraft) may be commonly held in another.
They are also warned to take socioeconomic and cultural differences into
account as there has been some evidence of over-diagnosing this disease within
some ethnic groups. 168
C. The Course of Schizophrenia
'"The median age at onset for the first psychotic episode of Schizophrenia is
in the early to mid-20s for men and in the late 20s for women."169 The onset of
the disease may be sudden or insidious. 170 The majority of individuals slowly
develop certain signs and symptoms such as "social withdrawal, loss of interest
in work or school, deterioration in hygiene or grooming, unusual behavior,
[and] outbursts of anger."171 Eventually, however, the active-phase symptoms
of the disease appear.172
The course of this disease varies from person to person, but "is often
unpredictable and can change rapidly."173 Some individuals display periodic
exacerbations and remissions of the disease while others remain chronically
ill.174 Complete remission, however, is uncommon in this disorder 175 and a
"substantial number of patients continue to manifest symptoms of
schizophrenia throughout their lives."176 The negative symptoms of the disease
are particularly persistent over the course of the illness. 177 Persons with
schizophrenia are also at a higher risk for suicide. Suicide is the number one
cause of premature death among individuals with schizophrenia (ten to fifteen
percent of persons with schizophrenia commit suicide).1 78

16 7

d. at 281.

16 8

Id.

16 9

APA, supra note 148, at 282.

170

d.

171

1d.

172
73

1

1d.
BETSY S. VOURLEKIS & ROBERTA R. GREENE, SOCIAL WORK CASE MANAGEMENT 112

(1992).
174
APA, supra note 148, at 282.
175
1d.
1 76

OFFICE OF TECHNOLOGY AssEssMENT, supra note 135, at 51.

1 77

APA, supra note 148, at 282-83.

1 78

0FFICE OF TECHNOLOGY ASSESSMENT, supra note 135, at 52.
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There is no cure for schizophrenia, but medication can be used to control the
psychotic symptoms, such as hallucinations and delusions. 179 However, such
antipsychotic medications have a number of troublesome side effects, and are
not effective for the negative symptoms of the disease.18 0 Some commentators
suggest that the pharmacologic approach, i.e., treatment by drugs, to treating
schizophrenia is grossly over-rated, and that medication plus psychosocial
treatment, a rarity, is more beneficial in treating this disease. 181
V. THE UNIQUE PROBLEM OF SCHIZOPHRENIA AND INFORMED CONSENT

Given the fact that schizophrenia is a cognitive disorder which can "impair[]
the ability to integrate information, to reason, to concentrate, or to focus
attention or purpose," 182 do individuals with this disorder have trouble
understanding information conveyed during the informed consent process?
Research by Paul R. Benson indicates that the answer to this question is "yes,"
though understanding can be improved if innovative methods of information
delivery are used, as opposed to the traditional method in which the unassisted
psychiatric researcher conveys the information to the subject.183 Also, research
by Thomas Grisso and Paul S. Appelbaum indicates there is "a greater risk of
very poor understanding of treatment disclosures among schizophrenic
patients." 184
Benson, with four colleagues, directly observed eighty-eight consent
sessions, looking at investigator information disclosure and subject

understanding in four psychiatric research settings. 185 They noted that their
research differed greatly from previous research on informed consent because
previous researchers had not focused on the directobservation of the interaction
between subject and researcher, citing this as a deficiency in past informed
consent research. 186
The Benson study observed and taped the consent process in eighty-eight
consent sessions involving twenty-four subjects diagnosed with major
depression, forty-four subjects diagnosed with chronic schizophrenia (all
living in the community), and twenty subjects diagnosed with borderline

17 9 CARSON & BUTcHER, supra note 138, at 613.
180

Jd. at 613-14.

181/d. at 464-66.
182 0FFICE OF TECHNOLOGY ASSESSMENT, supra note 135, at 47.

183 Paul R. Benson et al., Information Disclosure, Subject Understanding,and Informed
Consentin PsychiatricResearch,12 LAW & HUM. BEHAV. 455 (1988).
1 84

Thomas Grisso & Paul S. Appelbaum, Mentally Ill and Non-Mentally Ill Patients'
Abilities to UnderstandInformed ConsentDisclosuresforMedication,15 LAw & HuM. BEHAV.

377, 386 (1991).
18 5

Benson et al., supra note 183, at 455.

186

1d. at 456-57.
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personality disorder.187 Following each disclosure session between
investigator and subject, "subjects were questioned regarding their
understanding of the psychiatric research project using a semi-structured
interview," and they were also questioned as to "the consent process itself and
the requirements of their prospective roles as a psychiatric study
participant."188 Standardized interactional rating forms were completed by the
observers. 189
The Benson study used four different disclosure techniques to ascertain
whether information delivery and subject understanding could be
improved. 190 The following disclosure techniques were used: 1) unassisted
disclosure in which the subject's consent was obtained in the psychiatric
researcher's traditional manner; 2) unassisted disclosure with videotape in
which the subject received disclosure from the researcher and viewed an
informational videotape prepared by the researcher; 3) assisted disclosure with
"improved" videotape in which the subject viewed a second instructional tape
and "received whatever additional information the investigator deemed
appropriate to disclose"; and 4) disclosure provided to the subject by a "neutral
educator" and the researcher. 191
The Benson results show that the three innovative disclosure methods
significantly improved the quality of information communicated to subjects,
with the neutral educator method showing the largest improvement. 192 The
results further indicated that subject understanding showed "substantive
improvement" especially with the use of the neutral educator. 193 However, for
the subjects with schizophrenia, Benson found that the degree of improvement
was substantially lower compared to those with major depression and those
with borderline personality disorder.194 Benson concluded:
Findings indicate that the use of experimental techniques generally
increases the quality of information delivered to prospective subjects,
with disclosures by subject educators generating the most complete
information. Subject understanding was also found to be significantly
associated with the quality of information provided. Diagnosis and
187

1d. at 459.

188

d.

189

Benson et al., supra note 183, at 459.

190

d. at 457-58.
1 d. at 458.
192
1d. at 463-64 (showing that third party neutral educators, as opposed to researchers,
91

give more detailed information to subjects, explain more clearly that participation in the

research is voluntary, and allow more time for subjects to read consent forms. The

educators are to assist in understanding, in a neutral fashion, as they are not advocates

for either side).
193
194

Benson et al., supra note 183, at 469.

d. at 473.
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level of psychopathology, however, were found to be the most
important predictors of subject understanding, with schizophrenics
and the highly impaired most likely to demonstrate poor
comprehension. These results suggest that the degree of improvement
in understanding obtainable for severely
disordered subjects is
195
substantially lower than it is for others.
In another study, Grisso and Appelbaum compared the abilities of two
groups of hospitalized mentally ill patients (schizophrenia and major
depression) with two groups of hospitalized non-mentally ill patients (heart
disease and non-ill primary care patients) to understand informed consent
disclosures about treatment with medication. 196 Understanding of information
was determined by the patient's ability to paraphrase the information given to
him or her regarding treatment, and by the patient indicating, by choosing from
various statements, whether each statement is the "same" or "different" from
the information disclosed to him or her.197
The Grisso and Appelbaum results show that "the group of hospitalized
schizophrenic patients manifested significantly poorer understanding of
information related to decisions about consent to treatment with medication"
in comparison to the others. 198 They noted that, among those with
schizophrenia, the risk of poorer understanding was more likely. The risk of
poorer understanding also existed for those with major depression, but to a
lesser extent.199
These studies indicate that persons with schizophrenia have special needs
that deserve extra attention from the DHHS regulations akin to the additional
protections already provided to pregnant women, prisoners, and children. 200
The informed consent process has come under attack as an "empty ritual,"201
where "researchers concentrate more on obtaining signatures than on talking
and listening to the patients." 202 This process further deteriorates when persons
with cognitive problems are involved. Stricter overall regulations may be
195

1d. at 455.

196

Grisso &Appelbaum, supra note 184, at 377.

197

1d. at 379-81.
1981d. at 385.
199

1d. at 386.
See supra parts III.C.2-4.
201Katz, supra note 9, at 13-14.
200

202

David L. Wheeler, Informed ConsentQuestioned in Research Using Humans, CHRON.

HIGHER EDUC., Dec. 4,1991, at A14. In this short article, Arthur Caplan, then director of

the Center for Biomedical Ethics at the University of Minnesota, now at the Center for
Bioethics at the University of Penmsylvania (and the third witness at the congressional
hearing on May 23,1994) is quoted as saying, "[ilf Ihaveone more medical student come
up to me with a piece of paper in hand and say, 'I have informed consent,' I'm going to
amputate an arm."
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needed in this area, and are certainly needed where vulnerable subjects, such
as those with severe psychiatric disabilities, are concerned.
VI. SUGGESTED IDEAS FOR PROVIDING ADDITIONAL PROTECTIONS TO PERSONS
WITH SEVERE PSYCHIATRIC DISABILITIES, SUCH AS SCHIZOPHRENIA,

INVOLVED AS SUBJECTS IN RESEARCH
Several commentators have proposed suggestions indicating that the
mentally disabled, involved as subjects in research, could be better protected.
This writer will present an overview of these ideas.
Some ideas from the congressional hearing include: 1) to create a federal
oversight board to perform special reviews of some research involving
vulnerable groups and to make periodic visits to IRBs; 203 2) to require IRB
members to be more active in protecting subjects by having contact with
research participants beyond sitting in committee rooms reviewing research
and consent forms;204 3) to create special regulations for research involving the
mentally ill so that IRBs will have guidance in this area;205 and 4) to have at
least one subject representative on an IRB that reviews research involving
subjects with severe psychiatric disabilities. 206
Other suggestions, from various sources, include: 1) modifying the
informed consent process to improve upon information disclosure and
understanding through the use of innovative techniques, particularly the use
of independent subject educators; 207 2) increasing the monitoring/observation
of the informed consent process by IRB members which is an existing, but
infrequently used, part of the regulations; 2° 8 3) requiring a mandatory waiting
period between the investigator's request of the subject to participate in
research and the signing of the consent form; 209 and 4) using subject
211
advocates 210 to assist participants in understanding their rights.
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0 Problems in Securing Informed Consent of Subjects, supra note 2, at 20 (statement of

Arthur Caplan, Ph.D).
204

1d.

205

1d. at 32 (statement of Arthur Caplan, Ph.D); id. at 53 (statement of Donald

Rockwell, M.D.).
206

Problems in Securing Informed Consentof Subjects, supra note 2, at 46, 52 (statement

of Donald Rockwell, M.D.).
207
Benson et al., supra note 183, at 455, 471, 473.

208 Jesse A. Goldner, An Overview of Legal Controls on Human Experimentation and the
Regulatory Implications of Taking ProfessorKate Seriously,38 ST. Louis U. L.J. 63,132 (Fall
1993). The regulations allow an IRB "to observe or have a third party observe the consent

process." 45 C.F.R. § 46.109(e) (1994).
20 9 Goldner, supra note 208, at 133.

21OSubject advocates differ from subject educators in that educators explain the

research to subjects in a neutral manner (i.e., not on the side of the researchers or the
subjects) whereas advocates would act on the behalf of the subjects' interests.
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Other sources take a different view. They suggest that tighter regulations are
unnecessary and will only lead to the restriction of much needed research on
212
persons with schizophrenia.
VII. A PROPOSED SOLUTION TO PROVIDE TRUE PROTECTION FOR PERSONS WITH
SEVERE MENTAL DISABILITIES, SUCH AS SCHIZOPHRENIA,
INVOLVED AS SUBJECTS IN RESEARCH

This writer will now propose how the DHHS regulations could better protect
the forgotten group of persons with severe psychiatric disabilities, such as
those with schizophrenia, serving as research subjects. Clear and distinct
protections do not exist for this group of research participants, but are provided
for other vulnerable groups. The usefulness of each protection will be justified
by relying on the information regarding this particular population, although
the ultimate justification is the expectation that the federal regulations provide
additional protections to all groups considered vulnerable. The proposed
additions to the regulations will appear in italics followed by, in regular
typeface, the rationale for each one.
The proposed additions are as follows and are placed in a separate subpart
of the regulations devoted to this subgroup of participants:
Subpart E - Additional Protections Pertainingto Research Involving the Mentally
Disabled,Such as Persons With Schizophrenia,as Subjects.
§ 46.410 Applicability
(a) The regulations in this subpart are applicable to all research conducted or
supported by the Departmentof Health and Human Services involving the mentally
disabled, such as persons with schizophrenia, as subjects, and are applicable to all
researchregardlessof where the subjects may reside (in institutionalsettings or in the
community).
(b) The requirementsof this subpart are in addition to Subpart A of 45 C.F.R. Part
46.
§ 46.411 Purpose.
Inasmuch as persons with cognitive disabilities,such as those with schizophrenia,
may need extra assistance in considering whether or not to participatein research,
which could affect theirability to make a truly voluntary decision, the purpose of this
subpart is to provide additional safeguards for the protection of persons with
schizophreniainvolved as subjects in research.
§ 46.412 Ethical Advisory Boards.
(a) The creationof EthicalAdvisory Board(s),establishedby the Secretaryof DHHS.
Members of the Board,collectively, shall be competent to deal with medical, legal, social,

211STEvEN R. SMIH & ROBERT G. MEYER, LAW, BEHAVIOR, AND MENTAL HEALTH:
POLICY AND PRACTICE 211 (1987).
21 2 TORREY, supranote 132, at 332-34.
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ethical, and related issues releant to research involving the particularpopulation
within.
(b) To provide advice,at the request of the Secretary,to IRBs or researchers,on ethical
issues in research involving persons with severe psychiatric disabilities such as
schizophrenia.
These boards would be similar to the ones mandated to protect pregnant
women. 213 The justification for this additional safeguard is based on the fact
that schizophrenia is a complex disease involving potentially complex ethical
questions. For example, the ethics of the UCLA research, which withdrew
214
medication from subjects, is contested.
§ 46.413 Composition of Institutional Review Boards when research to be reviewed
involves persons with schizophrenia as subjects.
(a) At least one member of the Board shall be a person with schizophrenia to serve
as a subject representative,to represent the interestsof subjects.
(b) If the IRB is largerthan the minimally requiredfive members (per § 46.107(a)),
then the number of subject representatives should increase in proportion to the
enlargement of the Board. For example, if the Board contains ten members, two of the
ten shall be subject representatives.
This requirement is similar to the one for board composition of research
involving prisoners, 215 and is similar to a requirement that UCLA has been
ordered to follow. 2 16 This writer decided to deviate from the protections for
prisoners by adding the proportionality requirement in (b) to achieve
balance 217 and to have true subject representation as opposed to a token-like
version.
§ 46.414 Additional duties of the Institutional Review Boards in connection with
activitiesinvolving persons with schizophrenia.
(a) To provide, at a minimum, a subject educator to every potential research
participantto assist during each phase of informed consent (e.g., if a study consists of

21345 C.F.R. § 46.204 (1994).
214

See supra note 7.

21545 C.F.R. § 46.304(b) (1994).
2 16
Problems in Securing Informed Consent of Subjects, supra note 2, at 52 (statement of
Donald Rockwell, M.D.). UCLA is now under stricter scrutiny due to its schizophrenia

study, and has been ordered by the Office for Protection from Research Risks to include
a subject representative on its IRB when review entails psychiatric research. This is a
good plan that should be implemented overall, not just when a research facility is being
reprimanded for unethical behavior.
217 Unequal power relations between professional and lay members of review
committees have been recognized. PAUL M. McNEILL, THE ETHICS AND POLITICS OF
HUMAN EXPERIMENTATION 91-94, 188-92, 210-14 (1993). Since the subject representative
is likely, though not necessarily, to be a lay member, increasing the number of
representatives is important to achieve balance.
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multiple phases with informed consent obtainedateachphase, then the subject educator
is to be present at each stage). The subject educator must be properly trainedin such
areas as the elements of informed consent, be knowledgeable of the research study
involved, and be familiar with the potential needs of this subgroup. One subject
educatormay serve as educatorfor more than one subject, but not for more subjects
than could be reasonably served, allowing for adequate time to educate each subject.
The generalrequirements of informed consent (at § 46.116 (a)) must still be met.
with
This additional safeguard is justified by the fact that persons
2 18
schizophrenia, in general, can experience difficulty in comprehension.

(b)If the research involves more than minimal risk,219 a subject advocate must be
assigned to the activity site to determine if any unanticipated risks have arisen. The
subject advocate shall make periodic visits to the site, and may serve as an advocatefor
a reasonable number of subjects at a reasonable number of sites (a roving subject
advocate is allowable). The advocate must have the backgroundand experience to act
in the best interest of the subjects and may have no affiliation with the research or
investigators.
This requirement, based on an increase of risk in the research, is necessary
due to the fluid nature of schizophrenia and with the increased risk for suicide
among this population. 220 Considering these facts, increased monitoring is
warranted. Also, some, if not most, of the burden of monitoring should fall on
the research facility rather than solely on the subject's family.221
VIII. CONCLUSION

Modem history shows the world's attempt to protect research participants
from harm, from the Nuremberg Code established after the criminal
convictions of numerous physician-experimenters, 222 to our own country's
establishment of regulatory protections. 223 However, people are still being
harmed, as attested to by Gregory Aller, a research participant in a
schizophrenia study at UCLA. 224
While the regulations are designed to protect all research subjects, the
regulations also recognize that vulnerable subjects, with special circumstances,
deserve extra protection. For instance, pregnant women are given special

2 18

See supra part V.

2 19

See supra note 129 (for definition of"minimal risk").

22
22

0See supra notes 173-78 and accompanying text.
1See supra notes 143-44 and accompanying text.

222

Annas, supra note 35, at 120-22.
22345 C.F.R. §§ 46.101-46.409 (1994).
224 Problems in Securing Informed Consent of Subjects, supra note 2, at 4-9 (statement of

Gregory Aller).
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protections because of the third party (the fetus) involved, and prisoners are
given special protections because of the potentially coercive environment in
which they live.225 However, not all groups deemed "vulnerable" have been
afforded special protection, resulting in an unjust system. Persons with severe
mental disabilities, such as schizophrenia, have special circumstances
deserving of extra protection, yet no clear and distinct regulations govern
research involving this population.
Persons with schizophrenia, in general, may need extra time and assistance
in understanding information, and live with a condition that is somewhat
unpredictable. These are special circumstances warranting extra protection in
the areas of informed consent and monitoring for such research subjects. The
revelation of the Gregory Aller incident, followed by the concerns expressed at
the congressional hearing on May 23,1994,226 show that it is time to update the
regulations to provide true protection for persons with severe mental
disabilities, such as schizophrenia, serving as research subjects.
ANNE

22545 C.F.R. § 46 (Subpart B, Subpart C) (1994).
226

See generally Problems in Securing Informed Consent of Subjects, supra note 2.
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